Premium
The Dohner fluorescence in situ hybridization prognostic classification of chronic lymphocytic leukaemia ( CLL ): the CLL Research Consortium experience
Author(s) -
Van Dyke Daniel L.,
Werner Lillian,
Rassenti Laura Z.,
Neuberg Donna,
Ghia Emanuella,
Heerema Nyla A.,
Dal Cin Paola,
Dell Aquila Marie,
Sreekantaiah Chandrika,
Greaves Andrew W.,
Kipps Thomas J.,
Kay Neil E.
Publication year - 2016
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.13933
Subject(s) - fluorescence in situ hybridization , cohort , survival analysis , ighv@ , medicine , biology , oncology , chronic lymphocytic leukemia , genetics , chromosome , leukemia , gene
Summary This study revisited the Dohner prognostic hierarchy in a cohort of 1585 well‐documented patients with chronic lymphocytic leukaemia. The duration of both time to first treatment ( TTFT ) and overall survival ( OS ) were significantly longer than observed previously, and this is at least partly due to improved therapeutic options. Deletion 13q remains the most favourable prognostic group with median TTFT and OS from fluorescence in situ hybridization ( FISH ) testing of 72 months and >12 years, respectively. Deletion 11q had the poorest median TTFT (22 months) and 17p deletion the poorest median OS (5 years). The percentages of abnormal nuclei were significantly associated with differential TTFT for the trisomy 12, 13q and 17p deletion cohorts but not for the 11q deletion cohort. From the date of the first FISH study, patients with >85% 13q deletion nuclei had a notably shorter TTFT (24 months). Patients with ≤20% 17p deletion nuclei had longer median TTFT and OS from the date of the first FISH study (44 months and 11 years), and were more likely to be IGHV mutated.